BGB-A3055
- Generic Name
- BGB-A3055
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced Solid TumorMetastatic Solid TumorSolid Tumor
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 263
- Registration Number
- NCT05935098
- Locations
- 🇺🇸
Advent Health Cancer Institute, Orlando, Florida, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath